Roth Capital lowered the firm’s price target on Biofrontera Inc. (BFRI) to $9 from $10 and keeps a Buy rating on the shares. The firm is updating its model with higher cost of goods sold to reflect the impact of tariffs, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera Approves Key Proposals at Special Meeting
- Biofrontera says last patient completes treatment in Phase 3 study of Ameluz
- Biofrontera, Inc. Reports Record Sales Amid Strategic Growth
- Biofrontera announces last-patient-out in Phase 2b study of Ameluz topical gel
- Biofrontera Inc. Reports Revenue Growth Amid Strategic Restructuring